# Dr. Catherine Mullen — Schedule I Registration Path for AZ Biotech Startup

**Agent:** `psy_reg_001` — Dr. Catherine Mullen, PhD in Regulatory Science — Controlled Substances
**Division:** psychedelic_specialist
**Backend:** CroweLM Supreme (Claude Opus via Azure AI Foundry)
**Date:** 2026-04-21

## Query

A US-based biotech startup wants to begin in vitro characterization
of psilocybin analogs at a new 1,500 sq ft rented commercial laboratory in
Phoenix, AZ. They plan to hold no more than 2 grams total of Schedule I
substances at any time. No human or animal work — purely receptor binding
assays and analytical chemistry.

Walk them through the DEA Schedule I registration path. Specifically cover:

  1. What registration type they need (researcher vs analytical lab)
  2. What parts of 21 CFR 1301 apply to their specific situation
  3. Realistic timeline from decision-to-apply to DEA-issued registration
  4. Top three most likely reasons their application gets rejected or delayed,
     and how to preempt each
  5. Whether they also need an FDA IND given their in-vitro-only scope
  6. What state-level Arizona considerations apply

Be specific. Cite CFR sections by number. Flag [LEGAL REVIEW] items where
outside counsel input is required rather than general guidance.

## Response



# DRAFT — NOT FOR SUBMISSION WITHOUT COUNSEL REVIEW

# DEA Schedule I Researcher Registration Pathway
## In Vitro Characterization of Psilocybin Analogs — Phoenix, AZ Facility

**Prepared for:** [Startup Name Redacted]
**Date:** [Draft Date]
**Author:** Dr. Catherine Mullen, PhD — Regulatory Science, Controlled Substances

---

## 1. REGISTRATION TYPE: RESEARCHER vs. ANALYTICAL LABORATORY

This is the first fork in the road, and it matters more than most applicants realize.

### 1A. The Two Relevant Registration Categories

DEA issues Schedule I registrations under two primary activity codes relevant here:

| Activity Code | DEA Form | Governing CFR | Typical Registrant |
|---|---|---|---|
| **Schedule I Researcher** (Activity Code "C") | **DEA Form 225** | 21 CFR 1301.11(a), 1301.13, 1301.18 | Academic labs, pharma sponsors, CROs conducting pharmacological research |
| **Analytical Laboratory** (Activity Code "L") | **DEA Form 225** (same form, different box) | 21 CFR 1301.11(a), 1301.13(e)(1)(iv) | Forensic labs, reference-standard testing, quality-control assays |

### 1B. Recommendation: Register as Schedule I Researcher (Activity Code C)

**Rationale:**

Your described work — receptor binding assays and analytical chemistry on psilocybin analogs — is **pharmacological research**, not mere identity or purity testing of known substances. You are characterizing novel structural analogs for their receptor binding profiles. This is scientific investigation, not quality-control analytics.

The analytical laboratory registration is narrowly scoped. Per 21 CFR 1301.13(e)(1)(iv), it contemplates activities like forensic identification, reference standard verification, and method validation on substances whose pharmacological profile is already established. DEA has historically scrutinized analytical-lab registrants who drift into pharmacological characterization, treating it as an unauthorized expansion of registration scope. The MAPS PBC early-stage programs and the Johns Hopkins Center for Psychedelic and Consciousness Research both hold researcher registrations for in vitro and preclinical work of the type you describe.

**Bottom line:** File as a Schedule I Researcher. It is the broader, safer registration. If you register as an analytical lab and a DEA investigator during pre-registration inspection determines your receptor binding assays constitute "research," your application gets kicked back and you restart the clock.

> **[LEGAL REVIEW]** Confirm with outside counsel that the specific assay portfolio (receptor binding panels, SAR studies on analogs) aligns with DEA's interpretation of "research" under 21 CFR 1301.18. If any analogs are not themselves explicitly scheduled but are structurally similar to psilocybin/psilocin, counsel must also assess Federal Analog Act (21 USC 813) exposure — addressed in Section 1C below.

### 1C. Critical Threshold Issue: The Federal Analog Act and Your Analogs

This is the sleeper issue that will shape the scope of your registration.

Under **21 USC 813** (Federal Analog Act), a substance that is:

1. **Substantially similar in chemical structure** to a Schedule I or II controlled substance, **AND**
2. Has a stimulant, depressant, or hallucinogenic effect **substantially similar** to such a substance, **OR** is represented as having such an effect

…is treated **as a Schedule I substance** for purposes of federal law, provided it is **intended for human consumption**. The "intended for human consumption" prong has been litigated extensively — see *United States v. Washam*, 312 F.3d 926 (8th Cir. 2002), and *McFadden v. United States*, 576 U.S. 186 (2015).

**Why this matters to you:** Your psilocybin analogs, even if not explicitly listed in 21 CFR 1308.11, may be de facto Schedule I under the Analog Act if DEA or DOJ determines they meet the two-prong test. For in vitro research with no human administration, the "intended for human consumption" prong is arguably not met — but DEA investigators do not always parse this distinction charitably during pre-registration review.

**Recommended approach (belt-and-suspenders):**

- In your DEA Form 225 research protocol, **list every analog by chemical name and structure** alongside the parent Schedule I substances (psilocybin — 21 CFR 1308.11(d)(20); psilocin — 1308.11(d)(21)).
- State explicitly that you are requesting authorization to handle both the scheduled parent compounds and the structural analogs.
- If DEA tells you the analogs are not scheduled and therefore do not require registration, **get that determination in writing** and retain it in your compliance file. An oral "you're fine" from a Diversion Investigator is worth nothing at audit.

> **[LEGAL REVIEW]** Counsel must evaluate each specific analog against the Analog Act two-prong test and advise whether to proactively list them on the Form 225 protocol or treat them as unscheduled. The conservative path is to list them. The risk of not listing them is a post-registration finding of unauthorized handling.

---

## 2. APPLICABLE SECTIONS OF 21 CFR 1301

Here is a section-by-section map of what applies to your specific fact pattern — a small commercial lab, rented space, 1,500 sq ft, ≤2 g Schedule I on hand, in vitro only, no dispensing to humans or animals.

### 2A. Registration Provisions

| CFR Section | Topic | Applicability to Your Scenario |
|---|---|---|
| **1301.11(a)** | Who must register | You. Any person who manufactures, distributes, imports, exports, or conducts research with Schedule I substances must obtain a DEA registration. No exemptions for small quantities. |
| **1301.13(a)-(e)** | Activity codes and registration classes | You select Activity Code C (Researcher, Schedule I). Your Form 225 will identify specific substances and the research protocol. |
| **1301.18** | Research protocols for Schedule I | **This is your core section.** You must submit a research protocol as part of Form 225. Protocol must describe: (a) the substances, (b) the nature and extent of the research, (c) the qualifications of the principal investigator, (d) the security provisions. DEA forwards the protocol to FDA for scientific-merit review (even for in vitro work — see Section 5 below). |
| **1301.32(a)** | Acquisition from other registrants | You will procure psilocybin from a DEA-registered Schedule I supplier (e.g., Usona Institute, NIDA Drug Supply Program, or a DEA-licensed custom synthesis house). You cannot purchase from unregistered sources. Each transaction requires DEA Form 222 (order form) or its electronic equivalent (CSOS). |
| **1301.33** | Frequency of registration renewal | Registration is valid for **one year** for Schedule I researchers (not the three-year cycle for lower schedules). Mark your calendar: renewal Form 225a must be submitted **45 days before expiration** per 1301.36(i). |

### 2B. Physical Security Provisions — This Is Where Most Startups Underinvest

| CFR Section | Requirement | What This Means for Your 1,500 sq ft Lab |
|---|---|---|
| **1301.71(a)** | General security obligation | You must maintain effective controls against theft and diversion "commensurate with the particular schedule and quantity of controlled substances." Schedule I triggers the **highest** tier of requirements regardless of quantity. Two grams does not reduce your obligations. |
| **1301.72(a)** | Schedule I and II storage — safe or vault | Schedule I substances must be stored in a **"substantially constructed steel cabinet"** or a **vault** meeting the specifications of 1301.72(a)(1)-(3) at minimum. For researchers, 1301.75(b) cross-references 1301.72. |
| **1301.72(a)(1)** | Safe/vault specifications | GSA-approved security container (Class 5, Federal Specification AA-F-358) **or** a vault constructed of reinforced concrete or equivalent, with a GSA-approved vault door, **or** if a safe, UL-rated TL-30 or better. |
| **1301.73** | Employee screening | Non-DEA-registered personnel with access to controlled substance storage areas must undergo background screening. You must document this. |
| **1301.74** | Other security controls | Alarm systems, access control, visitor logs. DEA Diversion Investigators will inspect and may require intrusion detection systems (IDS) with 24/7 central station monitoring. |
| **1301.75** | Researchers — specific provisions | Cross-references 1301.71-74 and applies them to researchers. No relaxation for small quantities. The pre-registration inspection will evaluate your compliance with all of these sections. |
| **1301.76** | Other research registrants — additional provisions | DEA can impose **additional** security conditions as a term of registration. Expect this for a startup with no compliance track record. |

#### Practical Security Build-Out Recommendations for Your Facility

This is drawn from what has passed DEA pre-registration inspections at comparable facilities (small CRO/startup scale):

1. **Dedicated controlled substances room** within the 1,500 sq ft footprint — ideally ≤100 sq ft, single-entry, no windows. If windows exist, they must have steel bars or be bricked/blocked.
2. **TL-30 rated safe** (e.g.,?"?"Jewel Vault or Hamilton, approximate cost $3,000–$8,000) — bolted to floor or wall per 1301.72(a)(3).
3. **Electronic access control** on the room door — badge + PIN at minimum; biometric preferred. Maintain electronic logs. 21 CFR 1301.74(b) requires knowing who accessed what, when.
4. **Intrusion detection system (IDS)** with **24/7 central station monitoring** — silent alarm to local law enforcement. DEA expects this for Schedule I. Motion sensors inside the CS room, door/window contacts, duress alarm at reception.
5. **Security cameras** covering the CS room entrance and the safe — 90-day retention minimum (DEA does not specify this in CFR, but Diversion Investigators routinely request it; Johns Hopkins and NYU psychedelic research programs retain 90+ days).
6. **Self-closing, self-locking door** on the CS room.

> **[LEGAL REVIEW]** Because this is a **rented** commercial space, counsel must review the lease to confirm: (a) landlord permits the security modifications (safe bolting, door replacement, alarm installation); (b) lease term is at minimum co-terminus with the DEA registration period (1 year + renewals); and (c) landlord will not have unsupervised access to the CS room (or, if landlord retains master key access, the safe provides independent protection). DEA Diversion Investigators **will** ask about lease terms during the pre-registration inspection. A short-term or month-to-month lease is a red flag that has delayed registrations.

### 2C. Record-Keeping Provisions — 21 CFR 1304

| CFR Section | Requirement | Your Implementation |
|---|---|---|
| **1304.03** | Persons required to keep records | You, as a Schedule I registrant. |
| **1304.04(a)** | Maintenance of records | Records must be maintained at the **registered location** (your Phoenix lab) and be available for DEA inspection at all times during business hours. |
| **1304.11(a)** | Inventory requirements | You must conduct an **initial inventory** on the date registration is granted, and a **biennial inventory** every two years thereafter. Inventory must include exact count or weight (for Schedule I — no estimates permitted; 1304.11(e)(1)). |
| **1304.21** | General record-keeping for researchers | Every receipt, use, transfer, destruction, and return of Schedule I substances must be documented with: date, substance name, quantity, source/destination, signature of responsible party. |
| **1304.22** | Records for researchers | Specifically: name/address of supplier, date/quantity received, name/address of recipient (if transferring), date/quantity transferred, and for each research use a notation sufficient to trace consumption (bench log cross-references are acceptable). |
| **1304.33** | Reports to ARCOS (Automation of Reports and Consolidated Orders System) | Schedule I researchers report to DEA's ARCOS system. Your supplier will handle the distribution-side ARCOS report; you handle the receipt side. |
| **Retention** | **Minimum 2 years** from date of entry (1304.04(a)). Recommend retaining for the life of the registration + 3 years as a hedge against delayed audit cycles. |

#### Practical Record-Keeping System

Implement a **dual-record system**:
- **Bound paper log** (black ink, no white-out, line-through corrections with initials and date) — stored in the CS room or the safe.
- **Electronic spreadsheet or LIMS module** — password-protected, with audit trail (who edited what, when). Back up off-site weekly.

DEA Diversion Investigators can and do compare the two records for discrepancies. Any gram-level (or in your case, milligram-level) discrepancy between paper and electronic records triggers scrutiny.

---

## 3. REALISTIC TIMELINE: DECISION-TO-APPLY → DEA REGISTRATION IN HAND

I will be blunt: this takes longer than most startups expect. Here is a realistic Gantt based on current DEA processing times and comparable approvals at startup-scale facilities.

| Phase | Activity | Duration | Cumulative |
|---|---|---|---|
| **1** | Engage DEA-experienced outside counsel; retain a DEA compliance consultant | Weeks 1–2 | 2 weeks |
| **2** | Draft research protocol per 1301.18; identify PI, document PI qualifications (CV, publications, prior controlled-substance experience) | Weeks 2–6 | 6 weeks |
| **3** | Complete facility security build-out (safe, alarm, access control, cameras) | Weeks 3–10 | 10 weeks |
| **4** | Submit DEA Form 225 online via DEA Diversion Control Division website; pay application fee ($3,047 for 2024, researcher category) | Week 10–11 | 11 weeks |
| **5** | DEA Diversion Investigator (DI) assigned; DI reviews paper file | Weeks 12–20 | 20 weeks |
| **6** | DEA forwards protocol to FDA for scientific-merit review per 1301.18(a) | Weeks 12–24 (concurrent with DI review) | 24 weeks |
| **7** | DEA DI conducts **pre-registration on-site inspection** of Phoenix facility | Weeks 20–30 | 30 weeks |
| **8** | DI report filed; any deficiencies communicated; you remediate | Weeks 30–36 | 36 weeks |
| **9** | DEA Registration Unit final review and issuance | Weeks 36–44 | 44 weeks |

### Realistic total: **8 to 14 months** from decision-to-apply to Certificate of Registration in hand.

**Acceleration levers:**
- Having the facility **fully built out and inspection-ready** before submitting the Form 225 can shave 4–6 weeks (the DI can inspect immediately upon assignment rather than waiting for you to finish construction).
- A PI with **prior Schedule I registration history** (even at a different institution) signals lower risk and may expedite DI review.
- A **clean, well-drafted protocol** that anticipates DEA and FDA questions reduces rounds of deficiency letters.

**Deceleration factors:**
- DEA's Phoenix Field Division (DEA Phoenix District Office) workload varies. As of 2023–2024, the psychedelic research pipeline has increased application volume nationally. Some Field Divisions report 12+ month backlogs for Schedule I researcher applications.
- If FDA identifies deficiencies in the scientific protocol during the 1301.18(a) review, the clock stops until you respond.

> **[LEGAL REVIEW]** Counsel should confirm current processing times with the DEA Registration Unit (1-800-882-9539) before committing to internal project timelines. Processing times are not published and fluctuate.

---

## 4. TOP THREE MOST LIKELY REJECTION/DELAY CAUSES — AND PREEMPTION STRATEGIES

Based on published DEA administrative decisions, published audit findings, and my professional experience with comparable applications:

### REJECTION/DELAY CAUSE #1: Inadequate Physical Security at Pre-Registration Inspection

**What happens:** The DEA Diversion Investigator arrives at your Phoenix lab and finds the security build-out does not meet 21

---

> *Generated by Crowe Psychedelics `lfpsy agents invoke`. AI-drafted
> regulatory guidance for scoping only. All [LEGAL REVIEW] markers
> and final registration decisions must be resolved by DEA-registered
> counsel before any submission.*